| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Genitourinary Imaging |
1 From the Department of Radiology, Vera Cruz Hospital, Av Andrade Neves 707, Campinas SP, 13013-161, Brazil (A.P., A.P.B., E.M.O.); Department of Radiology, University of California, San Francisco (J.K.); and MRI Advanced Application Service, GE Medical Systems, São Paulo, Brazil (E.F.). Received April 5, 2004; revision requested June 15; revision received October 7; accepted November 11. Address correspondence to A.P. (e-mail: aprando{at}mpc.com.br).
PURPOSE: To prospectively evaluate the accuracy of transrectal ultrasonography (US)-guided biopsy directed with magnetic resonance (MR) spectroscopic imaging in patients with an elevated prostate specific antigen (PSA) level and negative findings at prior biopsy by using subsequent biopsy results as the reference standard.
MATERIALS AND METHODS: The committee on human research approved this study, and written informed consent was obtained. MR imaging and MR spectroscopic imaging were performed in 42 men (age range, 45–75 years; average age, 63.3 years; median age, 65 years) with negative findings at two or more prostatic biopsies and at digital rectal examination. MR spectroscopic data were rated on a scale of 1 (benign) to 5 (malignant) on the basis of standardized metabolic criteria. Abnormal voxels were overlaid on the corresponding transverse transrectal US images and used to perform voxel-guided biopsy of the prostate. All patients subsequently received an extended-pattern biopsy scheme.
RESULTS: Thirty-one of 42 patients demonstrated metabolic abnormalities that were suspicious for cancer (voxels with scores 
4). Eleven patients with negative MR spectroscopic imaging results also had negative biopsy findings. Cancer was detected in 17 (55%) of 31 men with positive MR spectroscopic imaging findings (voxels with scores 4) with a sensitivity of 100%, specificity of 44%, positive predictive value of 55%, negative predictive value of 100%, and accuracy of 67%. In men with at least one spectroscopic voxel with a score of 5 (12 of 17 men), the sensitivity, specificity, positive and negative predictive values, and accuracy were 71%, 84%, 75%, 81%, and 79%, respectively.
CONCLUSION: Metabolic data from MR spectroscopic imaging can be transferred to transrectal US images and used to sample regions of cancer in men with rising PSA levels and negative findings at prior biopsy with good accuracy.
© RSNA, 2005
This article has been cited by other articles:
|
|
 |
|
  H. Choi and J. Ma Use of Perfluorocarbon Compound in the Endorectal Coil to Improve MR Spectroscopy of the Prostate Am. J. Roentgenol., April 1, 2008; 190(4): 1055 - 1059. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Shukla-Dave, H. Hricak, C. Moskowitz, N. Ishill, O. Akin, K. Kuroiwa, J. Spector, M. Kumar, V. E. Reuter, J. A. Koutcher, et al. Detection of Prostate Cancer with MR Spectroscopic Imaging: An Expanded Paradigm Incorporating Polyamines Radiology, November 1, 2007; 245(2): 499 - 506. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. G. Costouros, F. V. Coakley, A. C. Westphalen, A. Qayyum, B. M. Yeh, B. N. Joe, and J. Kurhanewicz Diagnosis of Prostate Cancer in Patients with an Elevated Prostate-Specific Antigen Level: Role of Endorectal MRI and MR Spectroscopic Imaging Am. J. Roentgenol., March 1, 2007; 188(3): 812 - 816. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. J. Choi, J. K. Kim, N. Kim, K. W. Kim, E. K. Choi, and K.-S. Cho Functional MR Imaging of Prostate Cancer RadioGraphics, January 1, 2007; 27(1): 63 - 75. [Abstract] [Full Text] [PDF]
|
|
